Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

Haemophilia

Volumn 17, Issue 4, 2011, Pages 630-635

  Gringeri, A ^a   Fischer, K ^b   Karafoulidou, A ^c   Klamroth, R ^d   Lopez Fernandez M F ^e   Mancuso, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^e HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Bypassing agents; Haemophilia; Inhibitors; Surgery; Therapy; Unresponsive bleeds

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; D DIMER; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FIBRINOGEN BLOOD LEVEL; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LIMB DISEASE; LOWER LIMB COMPARTMENTAL SYNDROME; MAJOR SURGERY; PRIORITY JOURNAL; PROTHROMBIN TIME; SALVAGE THERAPY; SEQUENTIAL COMBINED BYPASSING THERAPY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION FACTORS; CHILD; DRUG THERAPY, COMBINATION; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79959509081     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02467.x     Document Type: Article

References (20)

1. Lloyd-Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
3. Gringeri A, Mannucci PM. Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
4. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation. B J Haematol 2006; 133: 591-605.
5. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
6. FEIBA. VH Anti-Inhibitor Coagulant Complex Package Insert. Westlake Village, CA: Baxter Healthcare Corporation, 2005.
7. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
8. Novo Nordisk A/S. NovoSeven Package Insert. Princeton, NJ: Novo Nordisk A/S, 2005.
9. Macik BG, Lindley CM, Lusher J et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coag Fibrinol 1993; 4: 521-7.
10. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
11. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
12. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Haemophilia 2002; 88: 60-5.
13. Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
14. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. B J Haematol 2006; 134: 314-9.
15. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
16. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
17. INTERSECT. Available at. Accessed October 25, 2010.
18. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. Thromb Haemost 2007; 5: 604-6.
19. Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia 2007; 13: 508-17.
20. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.